Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    The Schiehallion Fund

    MCap

    USD2,182m

    Last close

    USD2.15

    ▲ 159.85 (7,434.88%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Foxtons Group

    MCap

    GBP114m

    Last close

    GBP0.38

    ▲ −2.80 (−6.83%)

  • Sectors

    Sectors

    View All Sectors
  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

BioVersys (SIX: BIOV)

Last close As at 14/11/2026

CHF23.40

▲ −0.50 (−2.09%)

Market capitalisation

CHF138m

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focused on the development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria.

Latest News

Latest Insights

View More

Healthcare | SIX — flash

BioVersys — RIV-CARE FPFV raises the bar

Healthcare | Comment

BioVersys (SIX: BIOV) – RIV-CARE achieves first patient first visit

Healthcare | SIX — flash

BioVersys — Peer-reviewed data reinforce BV100’s potential

Healthcare | Comment

BioVersys (SIX: BIOV): Peer-reviewed data support BV100 profile

Share Price Chart

Market Data

Share Price CHF23.40
Market Cap CHF138m
52-Week High CHF30.70
52-Week Low CHF21.20
% Change 1M (6.8)
% Change 6M (11.7)
% Change 12M (8.2)
Ave. Daily Volume 1yr 2,384
Visit Website

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr. Marc Gitzinger

    CEO & Founder

  • Hernan Levett

    CFO

SIX — initiation

Healthcare

BioVersys — Targeting resistant and threatening indications